The use of levonorgestrel-releasing intrauterine devices in adolescents - own experience.

Ginekol Pol

Department of Woman's Health, School of Health Sciences in Katowice, Medical University of Silesia, Katowice, Poland, Katowice, Poland.

Published: October 2021

It is estimated that 19% of adolescents in Poland begin their sexual life when they are 15 years old and more than 50% of people aged 17-19 years have already had their first sexual contact. World Health Organization recommends teenagers to use the method of 'dual protection' (condom and other method of contraception, i.e. intrauterine devices). In this study, we sought to present our own experience in the field of the use of levonorgestrel-releasing intrauterine devices in adolescents and to compare it with the experience of other researchers worldwide. Low- dose levonorgestrel-releasing intrauterine device is safe and effective method of contraception in adolescents. It is also an alternative treatment used in heavy chronic abnormal uterine bleeding. It can be also used as an alternative in women with cyanotic heart disease who have contraindications for standard contraception. Gynecologists and pediatricians should be well informed in the topic of intrauterine device use among adolescents and they should provide them reliable knowledge in this field.

Download full-text PDF

Source
http://dx.doi.org/10.5603/GP.a2020.0054DOI Listing

Publication Analysis

Top Keywords

levonorgestrel-releasing intrauterine
12
intrauterine devices
12
devices adolescents
8
method contraception
8
intrauterine device
8
adolescents
5
adolescents experience
4
experience estimated
4
estimated 19%
4
19% adolescents
4

Similar Publications

Counsel patients that their Mirena IUD retains contraceptive effectiveness for extended use up to 8 years. The cumulative failure rate for years 6 through 8 was 0.68%, similar to reported rates for the first 5 years of use.

View Article and Find Full Text PDF

Fertility Sparing in Endometrial Cancer: Where Are We Now?

Cancers (Basel)

January 2025

Department of Molecular and Developmental Medicine, Obstetrics and Gynecological Clinic, University of Siena, 53100 Siena, Italy.

Endometrial cancer is the most common gynecological neoplasm with an increased incidence in the premenopausal population in recent decades. This raises the problem of managing endometrial cancer in fertile women who have not yet achieved pregnancy. In these women, after careful selection, hysterectomy may be postponed in favor of conservative management if specific requirements are met.

View Article and Find Full Text PDF

Purpose Of Review: Endometrial cancer (EC) is rising in incidence, particularly in younger, premenopausal women, due to increasing rates of obesity and delayed childbearing. This review evaluates current and emerging endocrine therapies, with a focus on fertility-preserving approaches for early-stage EC and treatment options for advanced or recurrent disease.

Recent Findings: Fertility-sparing endocrine therapies, such as medroxyprogesterone acetate, megestrol acetate, and levonorgestrel-releasing intrauterine devices, achieve high response rates but carry recurrence risks.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!